FDA Clears UroGen’s IND for UGN-501, Phase 1 Trial to Launch Q4 2026
URGN•The FDA has cleared UroGen’s IND application for UGN-501, enabling a Phase 1 intravesical study in non-muscle invasive bladder cancer patients slated for Q4 2026. UGN-501 is a next-generation oncolytic virus designed to destroy bladder tumor cells while inducing an anti-tumor immune response.
1. FDA Clearance of IND for UGN-501
The FDA has approved UroGen’s Investigational New Drug application for UGN-501, a next-generation oncolytic virus targeting non-muscle invasive bladder cancer. This clearance authorizes initiation of a Phase 1 clinical study assessing intravesical administration of the virus.
2. Phase 1 Study Plans
The first-in-human trial is set to begin in Q4 2026 and will evaluate safety, tolerability and feasibility of local intravesical delivery in NMIBC patients. Patient enrollment is expected to commence shortly after clearance, marking the start of clinical development.
3. UGN-501 Mechanism and Broader Potential
UGN-501 is engineered to selectively replicate within tumor cells, causing direct oncolysis and triggering an anti-tumor immune response. Preclinical data demonstrated cytotoxic activity across multiple bladder cancer cell lines, and UroGen sees potential for application in other solid tumors.
